



Domain Therapeutics raises EUR 2.11M (USD 2.8M)

Strasbourg, France, December 15, 2008 - Domain Therapeutics, a drug discovery company focused on the identification of allosteric modulators of G Protein-Coupled Receptors (GPCRs), announces today that it has successfully completed a new fundraising of EUR 2.11 million (USD 2.8 approx). New investors are AIRFI (Alsace Inter Regio Fonds d'Investissement), Alsace Création, Sam Eletr and Bernard Gilly. AGF Private Equity, Auriga Partners, EdRIP (Edmond de Rothschild Investment Partners) and Sofinnova Partners, all of which were already investors in the company, previously named Faust Pharmaceuticals, have also participated in the new round, thereby demonstrating their confidence in the company.

The money raised will go principally towards the early development of allosteric modulators targeting G Protein-coupled receptors (GPCRs) involved in major therapeutic indications. Domain Therapeutics has built up its pipeline using its proprietary technology platform. The pipeline consists of new chemical entities targeting hot receptors such as mGluR2, mGluR4 and GLP-1R for major indications including schizophrenia, Parkinson's disease and diabetes.

"This financing round shows that our technology is seen as relevant and having excellent potential," said Pascal Neuville, CEO of Domain Therapeutics. "We already have several products in our pipeline and the new funds mean we can develop them faster. And, given the current financial environment, the new investment is an even more encouraging endorsement of our technology."

"We wholeheartedly support Domain Therapeutics and are delighted to see that new investors have come into the company, confirming the big potential behind the company's technology," said Thierry Laugel, board member representing AGF Private Equity. "The maturity of the technology is convincing, the indications targeted have a high commercial value and the partnering programs currently being negotiated are also extremely promising."

About Domain Therapeutics S.A.

Domain Therapeutics is a biopharmaceutical company located in Strasbourg, France, dedicated to the discovery and early development of small molecules targeting G-coupled Protein Receptors (GPCRs), one of the best classes of drug targets. Domain Therapeutics is using its innovative and proprietary technology platform to identify orthosteric and allosteric ligands, including Silent Allosteric Modulators (SAMs) that represent a unique source of compounds that cannot be discovered by standard technologies. The platform is also able to address difficult GPCRs such as orphans and peptidic receptors. The company's pipeline is composed of new chemical entities ranging from hits to preclinical candidates targeting hot GPCRs for leading indications such as schizophrenia, Parkinson's disease and diabetes.

Contact Medias :**Andrew Lloyd & Associates**

Andrew Lloyd – Marie-Laure Melchior

andrew@ala.com - marilaure@ala.comTel : +33 1 56 54 07 00
